

Royal Stoke University Hospital

Ref: FOIA Reference 2019/20-335

Quality, Safety and Compliance Department
Newcastle Road
Stoke-on-Trent
Staffordshire
ST4 6QG

Date: 19th September 2019

Email foi@uhnm.nhs.uk

Dear

I am writing in response to your email dated 11th September 2019 requesting information under the Freedom of Information Act (2000) regarding biologics and biosimilar prescribing.

As of 1st November 2014 University Hospitals of North Midlands NHS Trust (UHNM) manages two hospital sites – Royal Stoke University Hospital, and County Hospital (Stafford). Therefore the response below is for the two sites combined from that date where appropriate.

I have a Freedom of Information request regarding biologics and biosimilar prescribing. Could you please provide me with the following numbers of patients treated in the last 12 months [latest 12 months possible] with the following drugs for the following conditions?

| Treatment | Total | Rheumatoid Arthritis | Ankylosing | Psoriatic Arthritis | Psoriasis | Crohns disease | Ulcerative |
|----------------------------------|-------|----------------------|-------------|---------------------|-----------|----------------|------------|
| | | | Spondylitis | | | | Colitis |
| Abatacout (Ovancia) | | | | | | | |
| Abatacept (Orencia) | | | | | | | |
| Adalimumab biosimilar [Amgevita] | | | | | | | |
| Adalimumab biosimilar [Hulio] | | | | | | | |
| Adalimumab [Humira] | | | | | | | |
| Adalimumab biosimilar [Hyrimoz] | | | | | | | |
| Adalimumab biosimilar [Imraldi] | | | | | | | |
| Apremilast (Otezla) | | | | | | | |
| Baricitinib (Olumiant) | | | | | | | |
| Brodalumab (Kyntheum) | | | | | | | |
| Certolizumab (Cimzia) | | | | | | | |
| Dimethyl Fumarate (Skilarence) | | | | | | | |
| Etanercept (Enbrel) | | | | | | | |
| Etanercept Biosimilar (Benepali) | | | | | | | |
| Etanercept Biosimilar (Erelzi) | | | | | | | |







| Golimumab (Simponi) | | | | |
|---------------------------------|--|--|--|--|
| Constitution (Transfer) | | | | |
| Guselkumab (Tremfya) | | | | |
| Infliximab [Flixabi] | | | | |
| Infliximab [Inflectra] | | | | |
| Infliximab [Remicade] | | | | |
| Infliximab [Remsima] | | | | |
| Ixekizumab (Taltz) | | | | |
| Rituximab (Mabthera) | | | | |
| Rituximab Biosimilar (Rixathon) | | | | |
| Rituximab Biosimilar (Truxima) | | | | |
| Sarilumab (Kevzara) | | | | |
| Secukinumab (Cosentyx) | | | | |
| Tildrakizumab (Ilumetri) | | | | |
| Tocilizumab (Ro Actemra) | | | | |
| Tofacitinib (Xeljanz) | | | | |
| Ustekinumab (Stelara) | | | | |
| Vedolizumab (Entyvio) | | | | |

We are unable to provide some of the information you require in the requested format as to release this data could lead to the identification of the person(s) involved due to the low numbers involved, and would breach the Trusts obligations under Data Protection Act 2018. Accordingly, this aspect of your request is exempt from disclosure under the terms of Section 40(2) of the FOI Act. *Personal information*. However as the Trust is committed to openness and transparency we can band the numbers as being <5. Please see below:

| Treatment | Total | Rheumatology | Dermatology | Gastroenterology |
|----------------------------------|-------|--------------|-------------|------------------|
| Abatacept (Orencia) | 0 | N/A | 0 | 0 |
| Adalimumab biosimilar [Amgevita] | <5 | N/A | 0 | <5 |
| Adalimumab biosimilar [Hulio] | 0 | N/A | 0 | 0 |
| Adalimumab [Humira] | 333 | N/A | 62 | 271 |
| Adalimumab biosimilar [Hyrimoz] | 277 | N/A | 71 | 206 |
| Adalimumab biosimilar [Imraldi] | 0 | N/A | 0 | 0 |







| Apremilast (Otezla) | 27 | N/A | 27 | 0 |
|----------------------------------|-----|-----|----|-----|
| Baricitinib (Olumiant) | 0 | N/A | 0 | 0 |
| Brodalumab (Kyntheum) | <5 | N/A | <5 | 0 |
| Certolizumab (Cimzia) | 0 | N/A | 0 | 0 |
| Dimethyl Fumarate (Skilarence) | 8 | N/A | 8 | 0 |
| Etanercept (Enbrel) | <5 | N/A | <5 | 0 |
| Etanercept Biosimilar (Benepali) | 0 | N/A | 0 | 0 |
| Etanercept Biosimilar (Erelzi) | <5 | N/A | <5 | 0 |
| Golimumab (Simponi) | <5 | N/A | 0 | <5 |
| Guselkumab (Tremfya) | 0 | N/A | 0 | 0 |
| Infliximab [Flixabi] | 0 | N/A | 0 | 0 |
| Infliximab [Inflectra] | 100 | N/A | 0 | 100 |
| Infliximab [Remicade] | 11 | N/A | 0 | 11 |
| Infliximab [Remsima] | <5 | N/A | 0 | <5 |
| lxekizumab (Taltz) | 5 | N/A | 5 | 0 |
| Rituximab (Mabthera) | 0 | N/A | 0 | 0 |
| Rituximab Biosimilar (Rixathon) | 0 | N/A | 0 | 0 |
| Rituximab Biosimilar (Truxima) | 0 | N/A | 0 | 0 |
| Sarilumab (Kevzara) | 0 | N/A | 0 | 0 |
| Secukinumab (Cosentyx) | 44 | N/A | 44 | 0 |
| Tildrakizumab (Ilumetri) | 0 | N/A | 0 | 0 |
| Tocilizumab (Ro Actemra) | 0 | N/A | 0 | 0 |
| Tofacitinib (Xeljanz) | <5 | N/A | 0 | <5 |
| Ustekinumab (Stelara) | 93 | N/A | 50 | 43 |
| Vedolizumab (Entyvio) | 51 | N/A | 0 | 51 |

Please see answers in table above.

 $\ensuremath{\text{N/A}}$ – we do not treat rheumatology patients at this Trust.







This refers to September 2018 – August 2019 data. We have excluded the paediatric specialty. A limitation to the accuracy of the data is any incorrect booking out on the computer system due to lack of information on the prescription.

We are unable to split by the conditions requested so have completed in the same format as previously i.e. gastroenterology and dermatology. (FOI ref 109-1920 May 2019 disclosure log) see below for web link.

*Please note that any individuals identified do not give consent for their personal data to be processed for the purposes of direct marketing.

UHNM NHS Trust is a public sector body and governed by EU law. FOI requestors should note that any new Trust requirements over the EU threshold will be subject to these regulations and will be advertised for open competition accordingly.

Where the Trust owns the copyright in information provided, you may re-use the information in line with the conditions set out in the Open Government Licence v3 which is available at http://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/. Where information was created by third parties, you should contact them directly for permission to re-use the information.

An anonymised copy of this request can be found on the Trust's disclosure log, please note that all requests can be found at the following link: http://www.uhnm.nhs.uk/aboutus/Statutory-Policies-and-Procedures/Pages/Freedom-of-Information-Disclosure-Log.aspx

This letter confirms the completion of this request. A log of this request and a copy of this letter will be held by the Trust.

If you have any queries related to the response provided please in the first instance contact my office.

Should you have a complaint about the response or the handling of your request, please also contact my office to request a review of this. If having exhausted the Trust's FOIA complaints process you are still not satisfied, you are entitled to approach the Information Commissioner's Office (ICO) and request an assessment of the manner in which the Trust has managed your request.

The Information Commissioner may be contacted at:

Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire SK9 5AF or via www.ico.org.uk.

If following review of the responses I can be of any further assistance please contact my secretary on 01782 676474.

Yours,







Lean Cennert.

Jean Lehnert Information Governance Manager



